Roivant Sciences Ltd. officer Eric Venker filed a Form 144 notice on November 3, 2026, disclosing a proposed sale of 200,000 common shares with an aggregate market value of $7,262,568.00, to be executed through Rockefeller Financial LLC on NASDAQ.

Key Highlights

  • Proposed sale: Eric Venker, an officer of Roivant Sciences Ltd., proposes to sell 200,000 common shares with an aggregate market value of $7,262,568.00.
  • Broker: The sale is to be executed through Rockefeller Financial LLC, 45 Rockefeller Plaza, Floor 5, New York, NY 10111.
  • Approximate sale date: November 3, 2026, on NASDAQ.
  • Shares outstanding: According to the filing, 722,323,015 common shares were outstanding at the time of notice.
  • 10b5-1 plan: The filing states the shares "will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026."
  • Prior three-month sales: Venker sold a total of 813,909 common shares in four transactions between August 20, 2026, and October 28, 2026, generating combined gross proceeds of $29,323,968.86.
  • Source of shares: The shares proposed for sale were acquired through options exercises and RSU grants originating from grant dates as early as May 20, 2020.

Venker's Proposed Sale and Recent Transaction History at Roivant Sciences

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Eric Venker, identified as an officer of Roivant Sciences Ltd. (NASDAQ:ROIV), intends to sell 200,000 common shares with an aggregate market value of $7,262,568.00. The notice was dated November 3, 2026, and lists the approximate date of sale as November 3, 2026, through broker Rockefeller Financial LLC in New York.

The filing discloses that the shares to be sold were acquired through a combination of options exercises and restricted stock unit (RSU) vesting events. Acquisition dates range from April 20, 2023, through September 19, 2025, and are tied to grant dates as early as May 20, 2020. Individual acquisition amounts listed in the filing include 32,753 shares from an options exercise on March 20, 2025; 5,459 shares from an RSU grant vesting on April 20, 2023; 96,078 shares from an options exercise on September 19, 2025; and several additional tranches across multiple dates, all sourced from Roivant Sciences Ltd.

In the three months preceding this notice, the filing shows that Venker sold common shares on four separate occasions: 13,909 shares on August 20, 2026, for gross proceeds of $512,407.56; 200,000 shares on August 28, 2026, for $7,147,087.91; 200,000 shares on September 30, 2026, for $7,323,556.00; 200,000 shares on October 20, 2026, for $7,023,153.39; and 200,000 shares on October 28, 2026, for $7,317,764.00. The filing indicates all activity is conducted under a Rule 10b5-1 trading plan adopted on June 30, 2026. The notice was signed by Carmen Zamores as a duly authorized representative of National Financial Services LLC, acting as attorney-in-fact for Eric Venker.

What Was Disclosed

Roivant Sciences Ltd. officer Eric Venker filed a Form 144 on November 3, 2026, notifying the SEC of a proposed sale of 200,000 common shares valued at $7,262,568.00, to be executed on NASDAQ pursuant to a 10b5-1 plan adopted June 30, 2026.